

USSN 09/554,533
Atty Docket No. 238/086US

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-54. (Canceled)

55. (New) A peptide compound of the formula:

His Xaa₂ Xaa₃ Gly Thr Phe Thr Xaa₈ Asp Xaa₁₀
Ser Lys Gln Xaa₁₄ Glu Glu Glu Ala Val Arg
Leu Xaa₂₂ Xaa₂₃ Glu Xaa₂₅ Leu Lys Xaa₂₈ Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro-Z,

wherein Xaa₂ is Ser, Gly or Thr,

Xaa₃ is Asp or Glu,

Xaa₈ is Ala, Ser, or Thr,

Xaa₁₀ is Leu, Ile, Val, pentylglycine or Met,

Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met,

Xaa₂₂ is Phe, Tyr or naphthylalanine,

Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met,

Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine,

Xaa₂₈ is Ala or Asn, and

Z is -OH or -NH₂; and

pharmaceutically acceptable salts thereof.

56. (New) The peptide compound of claim 55, wherein Xaa₂ is Ser.

57. (New) The peptide compound of claim 55, wherein Xaa₂ is Gly.

58. (New) The peptide compound of claim 55, wherein Xaa₃ is Asp.

USSN 09/554,533
Atty Docket No. 238/086US

59. (New) The peptide compound of claim 55, wherein Xaa₁₄ is Leu.

60. (New) The peptide compound of claim 55, wherein Xaa₂₅ is Phe.

61. (New) The peptide compound of claim 55, wherein Xaa₂₈ is Ala.

62. (New) The peptide compound of claim 55, wherein Z is NH₂.

63. (New) A peptide compound of the formula:

His Gly Glu Gly Thr Phe Thr Ser Asp Leu

Ser Lys Gln Xaa₁₄ Glu Glu Glu Ala Val Arg

Leu Phe Ile Glu Xaa₂₅ Leu Lys Asn-NH₂;

wherein Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;

Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine; and

wherein any one amino acid other than Xaa₄, Xaa₇, Xaa₉, Xaa₁₄, Xaa₁₈, Xaa₂₂ and Xaa₂₃

optionally is Ala; and pharmaceutically acceptable salts thereof.

64. (New) The peptide compound of claim 63, wherein Xaa₁₄ is Leu.

65. (New) The peptide compound of claim 63, wherein Xaa₂₅ is Phe.

66. (New) A peptide compound of the formula:

His Xaa₂ Xaa₃ Gly Thr Phe Thr Ser Asp Leu

Ser Lys Gln Met Glu Glu Glu Ala Val Arg

Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly

Pro Ser Ser Gly Ala Pro Pro Pro-Z,

wherein Xaa₂ is Gly, Ser, Ala or Thr, Xaa₃ is Glu or Asp; and Z is -OH or NH₂; and pharmaceutically acceptable salts thereof.

67. (New) The peptide compound of claim 66, wherein Xaa₂ is Ser.

USSN 09/554,533
Atty Docket No. 238/086US

68. (New) The peptide compound of claim 66, wherein Xaa₃ is Asp.

69. (New) The peptide compound of claim 66, wherein Z is NH₂.

70. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 55.

71. (New) The method of claim 70 further comprising the administration of a therapeutically effective amount of an insulin.

72. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 63.

73. (New) The method of claim 72 further comprising the administration of a therapeutically effective amount of an insulin.

74. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 66.

75. (New) The method of claim 74 further comprising the administration of a therapeutically effective amount of an insulin.